• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why M.D.C. Holdings Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

    1/18/24 7:52:18 AM ET
    $ARAV
    $CELU
    $CMMB
    $CTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARAV alert in real time by email

    Shares of M.D.C. Holdings, Inc. (NYSE:MDC) rose sharply in today’s pre-market trading.

    Sekisui House, Ltd. and M.D.C. Holdings announced an agreement pursuant to which a wholly-owned subsidiary of Sekisui House will acquire MDC in an all-cash deal with an equity value of $4.9 billion.

    M.D.C. shares surged 17.4% to $62.30 in pre-market trading

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Lytus Technologies Holdings PTV. Ltd. (NASDAQ:LYT) shares rose 137.3% to $0.2246 in pre-market trading after falling 5% on Wednesday.
    • Marpai, Inc. (NASDAQ:MRAI) shares jumped 29% to $1.09 in pre-market trading after declining over 8% on Wednesday. Marpai recently named John Powers as President.
    • Celularity Inc. (NASDAQ:CELU) shares climbed 25.8% to $0.2370 in pre-market trading after falling more than 5% on Wednesday.
    • Phunware, Inc. (NASDAQ:PHUN) shares gained 23% to $0.20 in pre-market trading. Phunware shares dipped 61% on Wednesday after the company announced pricing of a $7 million registered direct offering price at-the-market under Nasdaq rules.
    • Castellum, Inc. (NYSE:CTM) gained 22.2% to $0.3690 in pre-market trading after gaining 4% on Wednesday.
    • Roma Green Finance Limited (NASDAQ:ROMA) surged 20.1% to $1.37 in pre-market trading after tumbling over 70% on Wednesday.
    • Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) surged 15.8% to $0.9850 in pre-market trading after gaining over 7% on Wednesday.
    • New Horizon Aircraft Ltd. (NASDAQ:HOVR) gained 12.2% to $2.66 in pre-market trading after dipping 29% on Wednesday.
    • Deep Medicine Acquisition Corp. (NASDAQ:DMAQ) gained 10.6% to $8.05 in pre-market trading after dipping 9% on Wednesday.

    Losers

    • Aravive, Inc. (NASDAQ:ARAV) shares dipped 52.9% to $0.0520 in pre-market trading. Aravive intends to voluntarily terminate the listing of its common stock on the Nasdaq Global Select Market.
    • Nuvve Holding Corp. (NASDAQ:NVVE) shares fell 27% to $0.0740 in pre-market trading. Nuvve Holding will effect 1-for-40 reverse stock split, to be effective Jan. 19, 2024.
    • Airspan Networks Holdings Inc. (NASDAQ:MIMO) shares declined 19.1% to $0.1780 in pre-market trading. Airspan shares jumped 186% on Wednesday after the company announced a partnership with GCT Semiconductor to develop an RF module.
    • Newcourt Acquisition Corp (NASDAQ:NCAC) shares fell 19% to $9.40 in pre-market trading after gaining around 12% on Wednesday.
    • Warrantee Inc. (NASDAQ:WRNT) declined 18% to $0.2927 in pre-market trading after gaining 7% on Wednesday.
    • Plug Power Inc. (NASDAQ:PLUG) shares dipped 16.3% to $2.29 in pre-market trading. In a prospectus filed with the SEC, the company said it has entered into an at-market issuance sales agreement with B. Riley Securities regarding the sale of up to $1 billion in stock. The sale will be made from time to time, with B. Riley acting as a sales agent.
    • Chemomab Therapeutics Ltd. (NASDAQ:CMMB) shares fell 15.6% to $0.4555 in pre-market trading.
    • Meta Materials Inc. (NASDAQ:MMAT) shares declined 14% to $0.0656 in pre-market trading after gaining 5% on Wednesday.
    • Discover Financial Services (NYSE:DFS) fell 10.4% to $97.45 in pre-market trading after the company reported a 62% plunge in its profit for the fourth quarter on Wednesday.
    • Nukkleus Inc. (NASDAQ:NUKK) fell 6.4% to $1.32 after falling 6% on Wednesday. Nukkleus announced its intention to expand its investment in Jacobi Asset Management, known for sponsoring Europe’s first approved Bitcoin spot ETF.

     

    Now Read This: Fastenal, M&T Bank And 3 Stocks To Watch Heading Into Thursday

    Get the next $ARAV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARAV
    $CELU
    $CMMB
    $CTM

    CompanyDatePrice TargetRatingAnalyst
    Plug Power Inc.
    $PLUG
    1/9/2026$2.00Buy → Hold
    TD Cowen
    Discover Financial Services
    $DFS
    5/7/2025$180.00Buy → Hold
    Jefferies
    Plug Power Inc.
    $PLUG
    1/27/2025$1.00Neutral → Sell
    Seaport Research Partners
    Discover Financial Services
    $DFS
    1/13/2025$150.00 → $239.00Neutral → Buy
    UBS
    Discover Financial Services
    $DFS
    1/6/2025$137.00 → $186.00Equal Weight → Overweight
    Barclays
    Plug Power Inc.
    $PLUG
    11/14/2024Buy → Neutral
    BTIG Research
    Phunware Inc.
    $PHUN
    11/12/2024$9.00 → $6.00Buy → Neutral
    H.C. Wainwright
    Discover Financial Services
    $DFS
    6/7/2024Neutral
    BTIG Research
    More analyst ratings

    $ARAV
    $CELU
    $CMMB
    $CTM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

    NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry. REGISTER AND VIEW PRESENTATIONS HERE The presentations will be available 24/7 for 90 days. Investors,

    3/13/26 8:35:00 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio  Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing LANGHORNE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the consideration terms of its

    3/12/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

    Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications.Three pipeline 510(k) medical device pathway programs SPARK, FUSE, and ORCHID licensed to NEXGEL are potential market disruptors.Celularity will be the exclusive manufacturer of the licensed products at its FDA-compliant facility in Florham Park, New Jersey, where its vertically integrated manufacturing infrastructure is designed to support scalable, quality-driven production for both commercial-stage products and next-generation placental-derived cellular therapeutics. FLORHAM PARK, N.J., March 12, 2026

    3/12/26 8:30:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $ARAV
    $CELU
    $CMMB
    $CTM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Crespo Jose Luis bought $87,282 worth of shares (37,300 units at $2.34), increasing direct ownership by 14% to 307,332 units (SEC Form 4)

    4 - PLUG POWER INC (0001093691) (Issuer)

    12/17/25 9:06:21 PM ET
    $PLUG
    Industrial Machinery/Components
    Energy

    Director Eitan Yaron bought $100,000 worth of shares (100,000 units at $1.00), increasing direct ownership by 10% to 1,089,073 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:50:17 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Shiv Sagiv bought $50,000 worth of shares (50,000 units at $1.00), increasing direct ownership by 23% to 272,000 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:49:18 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $ARAV
    $CELU
    $CMMB
    $CTM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Parks Diane L. was granted 30,000 shares, increasing direct ownership by 6% to 520,021 units (SEC Form 4)

    4/A - Celularity Inc (0001752828) (Issuer)

    1/15/26 4:15:32 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Ling Geoffrey M.D. was granted 19,231 shares, increasing direct ownership by 8% to 256,026 units (SEC Form 4)

    4/A - Celularity Inc (0001752828) (Issuer)

    1/15/26 4:15:29 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Diamandis Peter was granted 20,385 shares, increasing direct ownership by 5% to 394,150 units (SEC Form 4)

    4/A - Celularity Inc (0001752828) (Issuer)

    1/15/26 4:15:31 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARAV
    $CELU
    $CMMB
    $CTM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Plug Power downgraded by TD Cowen with a new price target

    TD Cowen downgraded Plug Power from Buy to Hold and set a new price target of $2.00

    1/9/26 8:51:22 AM ET
    $PLUG
    Industrial Machinery/Components
    Energy

    Discover Financial Services downgraded by Jefferies with a new price target

    Jefferies downgraded Discover Financial Services from Buy to Hold and set a new price target of $180.00

    5/7/25 8:35:18 AM ET
    $DFS
    Finance: Consumer Services
    Finance

    Plug Power downgraded by Seaport Research Partners with a new price target

    Seaport Research Partners downgraded Plug Power from Neutral to Sell and set a new price target of $1.00

    1/27/25 8:08:33 AM ET
    $PLUG
    Industrial Machinery/Components
    Energy

    $ARAV
    $CELU
    $CMMB
    $CTM
    SEC Filings

    View All

    Cadrenal Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

    3/12/26 8:05:43 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Marpai Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Marpai, Inc. (0001844392) (Filer)

    3/11/26 8:28:32 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Plug Power Inc. filed SEC Form 8-K: Leadership Update

    8-K - PLUG POWER INC (0001093691) (Filer)

    3/10/26 4:01:01 PM ET
    $PLUG
    Industrial Machinery/Components
    Energy

    $ARAV
    $CELU
    $CMMB
    $CTM
    Leadership Updates

    Live Leadership Updates

    View All

    NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr

    3/10/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Plug Power Welcomes Jose Luis Crespo as Chief Executive Officer

    SLINGERLANDS, N.Y., March 03, 2026 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ:PLUG), a global leader in comprehensive hydrogen solutions, welcomes Jose Luis Crespo as Chief Executive Officer, marking the start of the Company's next phase of disciplined growth and focused execution. Crespo assumed the role on March 2, 2026. Crespo brings more than 12 years of leadership experience at Plug, most recently serving as President and Chief Revenue Officer, where he drove growth through cost discipline, margin expansion, and capital efficiency. He led Plug's commercial organization during a period of significant scale, helping grow revenue from approximately $27 million in 2013 to more than $700

    3/3/26 7:00:00 AM ET
    $PLUG
    Industrial Machinery/Components
    Energy

    Plug Power Calls on Stockholders to Act Now and Vote in Favor of Proposals at January 29, 2026 Special Meeting

    SLINGERLANDS, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ:PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, encourages stockholders to vote their shares ahead of the Company's Special Meeting of Stockholders (the "Special Meeting") scheduled for January 29, 2026. The Special Meeting includes proposals that are critical to supporting the Company's ongoing operations, financial flexibility and long-term growth strategy. The Board of Directors urges stockholders of record as of December 12, 2025 (the "Record Date") to vote their shares in favor of all proposals presented at the Special Meeting. This Special Meeting follows the Company's

    1/27/26 2:14:23 PM ET
    $PLUG
    Industrial Machinery/Components
    Energy

    $ARAV
    $CELU
    $CMMB
    $CTM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    12/9/24 5:14:07 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13D/A filed by Chemomab Therapeutics Ltd.

    SC 13D/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)

    11/29/24 3:04:59 PM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Chemomab Therapeutics Ltd.

    SC 13G - Chemomab Therapeutics Ltd. (0001534248) (Subject)

    11/21/24 10:59:28 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARAV
    $CELU
    $CMMB
    $CTM
    Financials

    Live finance-specific insights

    View All

    Plug Power Reports Q4 and Full Year 2025 Results with Strong Sales Growth and Margin Expansion

    Achieved Positive 4th Quarter 2025 Gross MarginSetting the Stage for 2026 Financial Targets SLINGERLANDS, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- Plug Power Inc., a global leader in comprehensive hydrogen solutions for the hydrogen economy, today announced financial results and operational milestones for the 4th quarter and fiscal year ended December 31, 2025, and outlined strategic priorities for 2026 and beyond. 2025 Goals in Review Achieved Over $700 million in revenueAchieved positive gross margin for Q4 2025Established strong liquidity platform to fund 2026Positioned Company to achieve the EBITDAS Q4 2026 goal This past year marked a pivotal commercial inflection point f

    3/2/26 4:01:00 PM ET
    $PLUG
    Industrial Machinery/Components
    Energy

    Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

    Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds.Orphan Drug and Fast Track designations from the FDA PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition of VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics ("Veralox"). The acquisition immediately strengthens Cadren

    12/11/25 8:05:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MARPAI REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    Continued Turnaround Driven by Cost Discipline and Operational Efficiency; Positioned for Strong 2026 Growth TAMPA, Fla., Nov. 12, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced third quarter 2025 results that mark another quarter of significant operational and financial improvement, underscoring the success of its transformation strategy and the Company's emergence as a disciplined, scalable growth platform heading into 2026. For the third quarter ended September 30, 2025, Marpai continued its turnaround trajectory, achieving meaningful advances in cost control,

    11/12/25 5:39:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care